Business

November 8, 2013

Investors applaud Salix acquisition

Wall Street gave a huge thumbs-up to Salix Pharmaceuticals’ plan to acquire specialty drug company Santarus for $2.6 billion.

Related content

Comments

Editor's Choice Videos